Halozyme Therapeutics (HALO) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.87 +1.28%
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +23.1%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $56.9 million versus the consensus estimate of $67.8 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $209.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
